Rufinamide: a new anti-epileptic medication

@article{Hakimian2007RufinamideAN,
  title={Rufinamide: a new anti-epileptic medication},
  author={Shahin Hakimian and Andrea Cheng-Hakimian and Gail D Anderson and John W. Miller},
  journal={Expert Opinion on Pharmacotherapy},
  year={2007},
  volume={8},
  pages={1931 - 1940}
}
Rufinamide (1-[2,6-difluorobenzyl]-1H-1,2,3-triazole-4-carboxamide) is a new anti-epileptic drug with a novel triazole derivative structure. The suspected mechanism of action is limitation of sodium-dependent action potentials, thought to result in a membrane stabilizing effect. Rufinamide is extensively metabolized in the liver by non-CYP450 enzymes with an elimination half-life of 8 – 12 h. Three randomized, placebo-controlled trials have shown that rufinamide is effective against partial… Expand
Rufinamide: A New Antiepileptic Medication for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
TLDR
The benefits of rufinamide include its pharmacokinetics, limited drug interactions, and lack of effect on cognitive function, but its use is limited by the rarity of LGS and the lack of comparative data with other antiepileptic agents. Expand
Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice.
TLDR
Rufinamide has been shown to be effective and generally well tolerated in children as young as one year and in adults, and it has been suggested that it might be preferred over other antiepileptic drugs as a second-line treatment for Lennox-Gastaut syndrome when drop attacks are frequent. Expand
Rufinamide from clinical trials to clinical practice in the United States and Europe.
TLDR
Individual case reports provide additional valuable information on how rufinamide is being used to treat different seizure types associated with LGS, and a comparison of the data reveals that a "lower and slower" dosing strategy tends to be adopted in clinical practice, in comparison with the clinical trial. Expand
Evaluation of WO2014121383 A1: a process for preparation of rufinamide and intermediates
TLDR
The manufacturing route appears to follow the regioselective Cu catalyzed cycloaddtion of 2,6-difluro benzyl azide with or without isolated activated acetylenic esters in three steps that provide a good lead for new synthetic strategy for the rufinamide synthesis. Expand
Chapter 9 – Antiepileptic Drugs
TLDR
There is a group of compounds, formally named the third generation, that offer the potential advantages of fewer drug interactions, unique mechanisms of action, and a broader spectrum of activity. Expand
Therapeutic Drug Monitoring of Antiepileptic Medications
TLDR
This chapter focuses on therapeutic drug monitoring of AEMs in treatment of epilepsy, emphasizing whether the pharmacokinetics and clinical profile of the drug make TDM useful. Expand
The Safety and Tolerability of Newer Antiepileptic Drugs in Children and Adolescents
TLDR
The safety and tolerability of seven new AEDs (levetiracetam, lamotrigine, oxcarbazepine, rufinamide, topiramate, vigabatrin and zonisamide) focusing on their side effect profiles and safety in children and adolescents are reviewed. Expand
Serum Concentrations of Rufinamide in Children and Adults With Epilepsy: The Influence of Dose, Age, and Comedication
TLDR
The results using generalized estimating equation regression models confirm a moderate but statistically significant nonlinear RUF concentration-dose relationship and indicate that oxcarbazepine and, especially, methsuximide decrease RUF concentrations as well. Expand
Pharmacological significance of triazole scaffold
TLDR
This paper is an attempt to review the pharmacological activities reported for triazole derivatives in the current literature with an update of recent research findings on this nuclei. Expand
Rufinamide treatment for refractory epilepsy in a largely pediatric population
TLDR
Rufinamide appears to be an effective, safe, and well-tolerated antiepileptic drug in the treatment of broad-spectrum intractable epilepsy, expanding outside its specific Food and Drug Administration approved usage in treatment of Lennox-Gastaut syndrome. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy
TLDR
Rufinamide has been shown, in this proof of principle trial, to be safe and effective in reducing seizure frequency in epileptic patients with no relevant influence on the metabolism of other AEDs. Expand
Efficacy and Safety of Rufinamide Adjunctive Therapy in Patients with Lennox–Gastaut Syndrome (LGS): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Trial
TLDR
The Late Breaking Science Abstracts highlight the most current research by neurologists, neuroscientists, and other applicable researchers whose work is of major scientific importance or interest, warranting expedited presentation and publication. Expand
The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers
TLDR
The effect of food on the pharmacokinetics of the antiepileptic rufinamide was investigated in healthy volunteers and the terminal half‐life was not influenced by concomitant intake of food. Expand
Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)
TLDR
A review of drugs in development and recently marketed AEDs and of a new antiepileptic device, the neurocybernetic prosthesis (NCP), has become available. Expand
Pharmacologic Treatment of the Catastrophic Epilepsies
TLDR
Treatment of the catastrophic epilepsies [infantile spasms, Lennox‐Gastaut syndrome, and progressive myoclonic epilepsy] remains a challenge to clinicians, and advances in the understanding of the etiologies, mechanisms, and genetics underlying the catastrophic epilepsy may facilitate more effective pharmacologic interventions. Expand
PHARMACOKINETICS OF A NEW ANTICONVULSANT(CGP 33101) IN EPILEPTIC MALE PATIENTS AND HEALTHY MALE SUBJECTS AFTER SINGLE ASCENDING ORAL DOSES OF 400–1200 mg
Information on the pharmacokinetic behavior of a new anticonvulsant agent (CGP 33101) was obtained after oral administration of ascending doses to male epileptic patients maintained on existingExpand
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
TLDR
This article summarizes the information presented on drugs in development, including brivaracetam, eslicarbazepine acetate, fluorofelbamate, ganaxolone, huperzine, lacosamide, retigabine, rufinamide, seletracetam, stiripentol, talampanel, valrocemide, JZP-4, NS1209, PID and RWJ-333369. Expand
The Effect of the New Antiepileptic Drug Rufinamide on Cognitive Functions
Summary:  Purpose: Rufinamide (RUF 331; 1‐(2,6‐difluoro‐phenyl)methyl‐1H‐1,2,3‐triazole‐4‐carboxamide) is a structurally novel compound that limits the frequency of sodium‐dependent neuronal actionExpand
Early identification of refractory epilepsy.
TLDR
Patients who have many seizures before therapy or who have an inadequate response to initial treatment with antiepileptic drugs are likely to have refractory epilepsy. Expand
Seizure recurrence after a 1st unprovoked seizure
TLDR
Depending upon clinical features, recurrence risk at 5 years following a 1st seizure ranged from 23% to 80%. Expand
...
1
2
3
4
5
...